Jardiance tablets: 10 mg or 25 mg, ketoacidosis and genital infections
Jardiance contains empagliflozin, an SGLT2 inhibitor that lowers blood sugar in type 2 diabetes by making the kidneys pass more glucose out in the urine. It is also authorised for heart failure and chronic kidney disease, so the same tablet may have been prescribed for a reason other than blood sugar. This page sets out the doses, the warnings about ketoacidosis, dehydration and genital infections, the side effects and what the doctor checks before prescribing it.
What Jardiance contains and which other products have empagliflozin
Jardiance is a film-coated tablet containing empagliflozin, an active substance from the group of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It is a tablet, not an injection, and it is not insulin. Jardiance is authorised centrally for the whole European Union, under EMA product number EMEA/H/C/002677, so its product information is published by the European Medicines Agency and the Medicines Authority register has no separate national entry for it.
The Medicines Authority register lists 10 authorised national medicines that contain empagliflozin on its own, in 10 mg and 25 mg strengths, all classed as prescription-only medicines (POM), and 20 authorised combination tablets with empagliflozin, also POM. Fixed combinations of empagliflozin with metformin and with linagliptin are also authorised centrally in the EU.
This matters in practice: if you already take a combination tablet, adding plain empagliflozin means taking the same substance twice. Check the composition on the pack rather than the name, and ask a pharmacist if the packs look different from what you expected.
What Jardiance is used for
According to the product information, Jardiance is used in adults and in children from 10 years of age to treat type 2 diabetes that is not well enough controlled, as an addition to diet and exercise. It can be used on its own when metformin is not suitable because it is not tolerated, or added to other diabetes medicines. Our page on metformin describes the medicine that is usually tried first.
In adults, Jardiance is also authorised for symptomatic chronic heart failure and for chronic kidney disease, with or without diabetes. If it was started for one of these reasons, say so in your answers, because the dose and the checks follow from the reason for treatment.
The medicine does not replace diet and physical activity. The package leaflet asks you to stay on the diet and exercise plan your doctor recommended. How type 2 diabetes presents is described in our guide to the symptoms of type 2 diabetes, and the other groups of diabetes medicines on our page on diabetes medicines.
How empagliflozin works
The kidneys filter glucose out of the blood and then take it back into the circulation, mainly through a transporter called SGLT2. Empagliflozin blocks that transporter, so part of the filtered glucose is not taken back and leaves the body in the urine. According to the product information, about 78 g of glucose a day was passed in the urine after four weeks of treatment, and blood sugar fell from the first dose.
The effect does not depend on the pancreas releasing more insulin, which is why the risk of low blood sugar is low when empagliflozin is used on its own or with metformin. The risk rises when it is combined with insulin or a sulfonylurea, and a lower dose of those medicines may then be considered.
The glucose passed in the urine also means a loss of calories, linked with a reduction in body fat and body weight, and the extra urine that goes with it may lower blood pressure moderately. The effect on blood sugar is judged on HbA1c compared with your result before treatment.
Doses in the product information
The dose is set by the doctor. You take the tablet once a day, at any time of day but preferably at the same time, with or without food, and swallow it whole with water.
| Use or situation | Dose in the product information |
|---|---|
| Type 2 diabetes, adults and children from 10 years | 10 mg once a day to start; can be increased to 25 mg once a day if 10 mg is tolerated, tighter control is needed and the eGFR is 60 mL/min/1.73 m² or more |
| Heart failure or chronic kidney disease, adults | 10 mg once a day |
| eGFR below 60 mL/min/1.73 m² | 10 mg once a day |
| eGFR below 20 mL/min/1.73 m² | Starting treatment is not recommended |
| Severe liver impairment | Not recommended |
Kidney function and the effect on blood sugar
In type 2 diabetes, the blood sugar-lowering effect of empagliflozin depends on kidney function. It is reduced when the eGFR falls below 45 mL/min/1.73 m² and is likely absent below 30, so the doctor considers adding another diabetes medicine if needed. The product information recommends checking kidney function before starting, at least once a year during treatment and before starting any other medicine that may harm the kidneys.
A small fall in eGFR at the start of treatment was seen in the studies and was generally temporary while treatment continued. Because of the way the medicine works, a urine test will show glucose while you take it, and one particular blood test of sugar control, the 1,5-AG assay, is unreliable; HbA1c remains the usual measure.
If you forget a tablet, the package leaflet says to take it as soon as you remember if your next dose is 12 hours or more away, and to skip it if it is less than 12 hours away. Do not take a double dose to make up for a forgotten tablet.
Ketoacidosis: why blood sugar may not warn you
Ketoacidosis, a serious build-up of ketones in the blood, has been reported with SGLT2 inhibitors, including empagliflozin, and some cases were life-threatening or fatal. The product information explains that in some cases blood sugar was only moderately raised, below 14 mmol/L (250 mg/dL), so a normal or near-normal reading on a home meter does not rule it out. It may also last longer after stopping than expected.
The risk is higher with prolonged fasting, a very restricted diet or severe dehydration, heavy alcohol use, a sudden reduction in insulin dose, a higher need for insulin because of surgery or serious illness, a history of pancreatitis and some forms of diabetes with little insulin production of your own. Treatment is interrupted if you are admitted to hospital for major surgery or a serious acute illness. Empagliflozin should not be used in type 1 diabetes.
- Feeling sick or being sick, stomach pain or loss of appetite
- Excessive thirst or rapid weight loss
- Fast and deep breathing or difficulty breathing
- Confusion, unusual sleepiness or tiredness
- A sweet smell on your breath, a sweet or metallic taste in your mouth, or a different smell to your urine or sweat
What to do if you notice signs of ketoacidosis
If you notice any of the signs listed above, stop taking Jardiance and contact a doctor or the nearest hospital at once, whatever your blood sugar reading. In an emergency, call 112 or go to Accident and Emergency. The product information does not recommend restarting an SGLT2 inhibitor after ketoacidosis unless another clear cause was found and dealt with.
The product information asks for factors that can lead to ketoacidosis to be considered before treatment starts, so tell the doctor if you have ever had pancreatitis, if you drink a lot of alcohol, if you are on a diet that strictly limits how much you eat, or if your insulin dose has recently been reduced.
Dehydration, low blood pressure and illness
The extra urine that comes with empagliflozin can lead to dehydration and a fall in blood pressure. The package leaflet lists unusual thirst, light-headedness or dizziness on standing, and fainting as possible signs. The product information asks for caution if a drop in blood pressure could be a risk, for example with heart disease, with blood pressure medicines and a history of low blood pressure, or at the age of 75 or over.
If you are being sick, have diarrhoea or a fever, or cannot eat or drink normally, the doctor may ask you to stop Jardiance until you recover, to prevent losing too much fluid. Contact the doctor who manages your treatment in that situation; do not decide the pause or the restart on your own.
Urinary and genital infections, including a rare serious one
Genital yeast infections (thrush) and urinary tract infections are common side effects. Genital infections were reported more often with empagliflozin than with placebo, more often in women, and they were mild or moderate. Complicated urinary infections, including kidney infection and urosepsis, have been reported, and the doctor may consider pausing treatment during such an infection. Burning when passing urine, cloudy urine, or pain in the pelvis or the middle of the back are signs of a urinary infection worth reporting.
A rare but serious infection of the skin and tissue between the genitals and the anus, called necrotising fasciitis of the perineum or Fournier's gangrene, has been reported in women and men taking SGLT2 inhibitors. Pain, tenderness, redness or swelling in the genital or perineal area together with fever or feeling unwell needs urgent medical attention; call 112 if you feel very unwell.
An increase in lower limb amputations, mainly of toes, was seen in long-term studies with another SGLT2 inhibitor; whether this applies to the whole group is not known. As for everyone with diabetes, routine care of your feet matters.
Who should not take Jardiance
The only formal contraindication in the product information is allergy to empagliflozin or to any other ingredient of the tablet. The product information also states that empagliflozin should not be used in type 1 diabetes, and the tablets contain lactose, so people with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take them.
It is not recommended to start empagliflozin with an eGFR below 20 mL/min/1.73 m² or in severe liver impairment. Pregnancy and breast-feeding are covered below.
Medicines that interact with empagliflozin
Diuretics, both thiazide and loop diuretics, add to the fluid loss and may increase the risk of dehydration and low blood pressure, especially in older people. Insulin and sulfonylureas increase the risk of low blood sugar, so a lower dose of those medicines may be needed. The package leaflet lists shaking, sweating, feeling very anxious or confused, a fast heartbeat, excessive hunger and headache as signs of low blood sugar, and the doctor tells you how to treat it.
Medicines that induce certain liver enzymes, such as rifampicin or phenytoin, may reduce the effect of empagliflozin; combining them is not recommended, and if it cannot be avoided, blood sugar control is monitored. Empagliflozin may lower blood levels of lithium, so the doctor who prescribes lithium checks its level more often after empagliflozin is started or its dose is changed.
Tell the doctor about every medicine you take, including non-prescription medicines and herbal products, and say if a new medicine that may affect the kidneys is planned.
Side effects listed in the product information
In the clinical studies in type 2 diabetes, side effects were about as frequent as with placebo; the most frequent was low blood sugar with a sulfonylurea or insulin. Swelling of the face, lips, mouth, tongue or throat that may make breathing or swallowing difficult can be a sign of a severe allergic reaction: the package leaflet asks you to contact a doctor or the nearest hospital at once.
| How often | Side effects in the product information |
|---|---|
| Very common (more than 1 in 10) | Low blood sugar when used with a sulfonylurea or insulin; loss of body fluid (dehydration, low blood pressure) |
| Common (up to 1 in 10) | Genital yeast infection and other genital infections; urinary tract infection; thirst; passing more urine than usual; constipation; itching; rash; raised blood fats |
| Uncommon (up to 1 in 100) | Ketoacidosis; hives; swelling of the face, lips or throat (angioedema); pain or straining when passing urine; blood tests showing reduced kidney function or a higher haematocrit |
| Rare (up to 1 in 1,000) | Necrotising fasciitis of the perineum (Fournier's gangrene) |
| Very rare (up to 1 in 10,000) | Inflammation of the kidneys (tubulointerstitial nephritis) |
What the studies showed about the heart
In the EMPA-REG OUTCOME study described in the product information, about 7,000 adults with type 2 diabetes and established cardiovascular disease took empagliflozin or placebo on top of their usual treatment and were followed for a median of 3.1 years. Death from cardiovascular causes occurred in 3.7% of those taking empagliflozin and in 5.9% of those taking placebo, and hospital admission for heart failure in 2.7% and 4.1%. These are results from a study population, not a prediction for any one person, and whether the medicine suits you depends on your own situation.
Pregnancy and breast-feeding
There are no data on empagliflozin in pregnant women. Animal studies have shown effects on development after birth, so, as a precaution, the product information says it is preferable to avoid Jardiance during pregnancy. If you are pregnant or planning a pregnancy, the treatment of your diabetes is reviewed by the doctor who manages it.
It is not known whether empagliflozin passes into human breast milk; in animals it does, and a risk to the baby cannot be excluded. Jardiance should not be used while breast-feeding.
How the doctor assesses a request for empagliflozin
You fill in a medical questionnaire about the medicine, your health and other medicines you take, whether empagliflozin has already been started for you or would be new to you. The doctor may ask for a recent HbA1c and a recent measure of kidney function, together with the reason the medicine was started. For a first prescription your answers need to give clear indications; otherwise the doctor may ask for further results, recommend that you see a doctor in Malta or decline.
If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. The warning signs above are never handled this way.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
What does it cost?
Two separate costs are involved. The button on this page shows the fee for the doctor's review, and the tablets themselves are paid for at the pharmacy, which can tell you the price of your pack. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.
Who reviews your request?
Your request is reviewed by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta.
Is Jardiance prescription-only in Malta?
Jardiance is authorised centrally in the European Union, and Annex II of its product information classes it as a medicinal product subject to medical prescription, which applies in Malta as in the other member states. The 10 national empagliflozin products in the Medicines Authority register are all prescription-only medicines (POM). A doctor decides whether to start it and at what dose, taking into account your kidney function, blood pressure, other diabetes medicines and any diuretic you take.
What is the usual dose of Jardiance?
In type 2 diabetes the starting dose is 10 mg once a day, which can be increased to 25 mg once a day if you tolerate 10 mg, need tighter control and your eGFR is 60 mL/min/1.73 m² or more. For heart failure and chronic kidney disease, and whenever the eGFR is below 60, the dose is 10 mg once a day. You take it with or without food and swallow it whole with water.
What are the most common side effects of empagliflozin?
Low blood sugar when it is combined with a sulfonylurea or insulin, and loss of body fluid, are very common. Genital yeast infections, urinary tract infections, thirst, passing more urine, constipation, itching, rash and raised blood fats are common. Ketoacidosis is uncommon but serious, and a severe infection of the genital area, Fournier's gangrene, is rare; both need urgent medical help.
Can ketoacidosis happen when blood sugar is normal?
With SGLT2 inhibitors it can occur when blood sugar is only moderately raised, below 14 mmol/L, so a near-normal reading does not rule it out. Feeling or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness and a sweet smell on the breath mean stopping Jardiance and contacting a doctor or the nearest hospital at once, whatever your blood sugar.
What should you do during a stomach bug while taking Jardiance?
Vomiting, diarrhoea, fever or being unable to eat or drink normally put you at risk of dehydration, and the package leaflet says the doctor may ask you to stop Jardiance until you recover. Contact the doctor who manages your treatment, and get urgent help if you notice signs of ketoacidosis or feel faint.
Can you stop Jardiance once your blood sugar is at target?
The package leaflet asks you not to stop Jardiance without consulting your doctor, unless you suspect ketoacidosis, and warns that in type 2 diabetes your blood sugar may rise when you stop. A result at target usually reflects the treatment. If side effects are the reason you want to stop, tell the doctor, because other groups of diabetes medicines exist.
Is Jardiance used for heart failure and kidney disease?
In adults, Jardiance is authorised for symptomatic chronic heart failure and for chronic kidney disease, as well as for type 2 diabetes. For both of those uses the dose is 10 mg once a day. If it was started by a cardiologist or a kidney clinic, say so in your answers, because the reason for treatment changes what the doctor needs to know.
Can a pharmacy in Malta dispense a prescription from a doctor in another EU country?
A prescription from a doctor in another EU country can be dispensed in Malta (Article 81(3) of the Medicines Act, Cap. 458) if the pharmacist can confirm the doctor's licence. The decision rests with the pharmacist, who may refuse. You bring the prescription on paper together with photo identification.
- EMA: Jardiance, European public assessment report (EMEA/H/C/002677)
- EMA: Jardiance product information (summary of product characteristics, Annex II and package leaflet)
- Medicines Authority: Emlygexa 10 mg film-coated tablets, empagliflozin (MA604/02301)
- EMA: Synjardy (empagliflozin and metformin), European public assessment report
- Medicines Authority: prescription-only and non-prescription medicines
- Medicines Act (Cap. 458), Article 81 (legislation.mt)
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Commission Implementing Directive 2012/52/EU on the recognition of medical prescriptions issued in another Member State (EUR-Lex)